Clinical data | |
---|---|
Pronunciation | /ˌɛsoʊˈmɛprəˌzoʊl, -ˈmiː-, -ˌzɒl/ |
Trade names | Nexium, many others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a699054 |
License data |
|
Pregnancy category |
|
Routes of administration |
Oral, IV |
ATC code | A02BC05 (WHO) |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 50 to 90% |
Metabolism | Hepatic (CYP2C19, CYP3A4) |
Biological half-life | 1–1.5 hours |
Excretion | 80% Renal 20% Faecal |
Identifiers | |
|
|
CAS Number | 119141-88-7 |
PubChem (CID) | 9579578 |
DrugBank | DB00736 |
ChemSpider | 7843323 |
UNII | N3PA6559FT |
KEGG | D07917 |
ChEBI | CHEBI:50275 |
ChEMBL | CHEMBL1201320 |
ECHA InfoCard | 100.149.303 |
Chemical and physical data | |
Formula | C17H19N3O3S |
Molar mass | 345.417 g/mol |
3D model (Jmol) | Interactive image |
|
|
|
|
(what is this?) |
Esomeprazole sold under the brand name Nexium (or Nexum) among others, is a proton-pump inhibitor which reduces stomach acid. It is used in the treatment of dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, and Zollinger-Ellison syndrome.
It decreases secretion of acid through inhibition of the H+/K+-ATPase in the parietal cells of the stomach. By inhibiting the functioning of this transporter, the drug prevents formation of stomach acid.
Esomeprazole is the (S)-(−)-enantiomer of omeprazole. Esomeprazole is currently sold over the counter in the US, the UK and Australia.
The primary uses of esomeprazole are gastroesophageal reflux disease, treatment and maintenance of erosive esophagitis, treatment of duodenal ulcers caused by H. pylori, prevention of gastric ulcers in those on chronic NSAID therapy, and treatment of gastrointestinal ulcers associated with Crohn's disease.
Gastroesophageal reflux disease (GERD) is a condition in which the digestive acid in the stomach comes in contact with the esophagus. The irritation caused by this disorder is known as heartburn. Long-term contact between gastric acids and the esophagus can cause permanent damage to the esophagus. Esomeprazole reduces the production of digestive acids, thus minimizing their effect on the esophagus.
Esomeprazole is combined with the antibiotics clarithromycin and amoxicillin (or metronidazole instead of amoxicillin in penicillin-hypersensitive patients) in a 10-day eradication triple therapy for Helicobacter pylori. Infection by H. pylori is a causative factor in the majority of peptic and duodenal ulcers.